John Proffett has over 20 years of life sciences business development experience. He participated and driven transactions ranging from discovery stage through multi-billion dollar M&A. John has experience in a wide range of therapeutic and technology areas, including central nervous system disorders, pain, autoimmune and rare diseases, oncology, drug delivery technology and drug-device combinations.
Prior to founding Shadow Lake Group Inc, John was the Director of Business Development & Licensing at Mallinckrodt Pharmaceuticals, where he completed a series of transactions through the company's spin out from Covidien – growing from a market cap of $2 billion to over $14 billion during his tenure. Prior to Mallinckrodt, John was Senior Director of Intellectual Property and Licensing at Neuromed Pharmaceuticals. Prior to that, he worked in the University Industry Liaison Office at the University of British Columbia, where he was responsible for life sciences technology licensing and start-up company formation.
John holds Bachelor's degrees in Biochemistry and Art History from the University of British Columbia.